Authors
Latest:
Study shows efficacy of stereotactic ablative body radiotherapy in kidney cancerTreatment with stereotactic ablative body radiotherapy resulted in no observed local failures or cancer-related deaths among patients with primary renal cell cancer.
Latest:
Conference Convenes Experts in the Field of Nuclear Medicine to Advance Prostate Cancer CareThe conference explored the current and future use of PSMA-PET imaging and PSMA radioligand therapy to improve the clinical care of patients with prostate cancer.
Latest:
How to perform office-based blue light cystoscopyBLC with hexaminolevulinate can be an easily replicable procedure in patients with non–muscle-invasive bladder cancer.
Latest:
Trends in coding audits and what physicians can expectRecent trends in medical audits and what physicians can expect with the CMS changes in 2021 to the documentation of E/M codes.
Latest:
Transurethral resection of the bladder tumor: Standard technique and new advancementsImprovement in imaging modalities may help in performance of transurethral resection of the bladder tumor.
Latest:
Smaller medical practices increasingly targeted for cyber attacksPatient data is so valuable — and smaller providers are more vulnerable — that hackers are increasingly targeting physician groups.
Latest:
Expert shares key cybersecurity fundamentals and best practicesCybersecurity training is vital because it is mandated by HIPAA.
Latest:
Future Directions for the Management of Advanced Prostate CancerBobby Liaw, MD; Vivek K. Narayan, MD, MS; Ashley E. Ross, MD, PhD; and Neal Shore, MD, FACS, provide closing thoughts and advice for the optimal management of advanced prostate cancer.
Latest:
Prostate Cancer Treatment: Incorporating Micronized Abiraterone into Clinical PracticeIn the second article of this series, Benjamin H. Lowentritt, MD, FACS, provides clinical insights on micronized abiraterone as a treatment for patients with prostate cancer.
Latest:
Phase 3 CELLEBRATE trial testing regenerative stem cell-based therapy to improve urinary control for womenThe therapy, known as Autologous Muscle Derived Cells for Urinary Sphincter Repair (iltamiocel), involves a medical procedure in which a participant’s own muscle cells are collected, processed, and then injected into the tissues of the urinary passage.
Latest:
Future Research and Development of Abiraterone Combination TherapiesIn this video, experts share their opinion on the potential for novel combination therapies involving micronized abiraterone, particularly in conjunction with PARP inhibitors like olaparib or niraparib, as evidenced in clinical trials such as PROpel and MAGNITUDE. Additionally, they highlight other potential novel combinations like abiraterone with prednisolone and enzalutamide (STAMPEDE trial), and the integration of abiraterone in treatments involving radiation and androgen deprivation therapy (ADT).
Latest:
Unmet Needs and Future Directions for Patients with Metastatic CSPCDr Gordon Brown closes his discussion on mCSPC by highlighting unmet needs in the field and ongoing initiatives that may address these needs.
Latest:
Expert urges widespread adoption of next-generation sequencing among physiciansNGS empowers clinicians to take proactive measures to prevent disease, enables more precise diagnosis, and provides better insight on the best treatment option.
Latest:
UT Money Matters: Roth IRA conversionsExpert insight on pros, cons and optimal strategies when considering converting a traditional IRA to a Roth IRA.
Latest:
How to implement an ERAS pathway in your urology practiceProgram encompasses patient counseling, anesthetic planning, and early mobilization.
Latest:
How to approach immune checkpoint inhibitor therapy in prostate cancerNext-generation sequencing identifies subtypes that may benefit from immune checkpoint inhibitors.
Latest:
Advanced bladder cancer patients could keep their bladder under new treatment regime, clinical trial showsAn approach combining chemotherapy and immunotherapy could help preserve quality of life.
Latest:
FDA accepts IND application for RAG-01 in NMIBCThe clearance of the IND application for RAG-01 will initiate the launch of clinical trials in the US.
Latest:
Emerging Therapies for Metastatic Castration-Resistant Prostate CancerRobert Dreicer, MD, describes the future of metastatic castration-resistant prostate cancer.
Latest:
Future Perspectives in the Treatment of Patients With Urinary StonesDrs Bechis and Semins discuss future developments in urinary stone management, emphasizing the potential for improved vacuum aspiration devices, combined intravenous and PCNL surgeries, and the hope for medications to dissolve stones.
Latest:
Demystifying Vector-Based Intravesical Gene Therapy for NMIBC: A New FrontierNeal Shore, MD, FACS, is a U.S. Chief Medical Officer at GenesisCare USA and Medical Director of the Carolina Urologic Research Center. He also was an investigator on the Phase 2 and 3 studies in the clinical trial program for nadofaragene firadenovec-vncg.
Latest:
PARP inhibitors: Treating mCRPC from a genetic basisTreatments provide a targeted therapeutic strategy for metastatic castration-resistant prostate cancer.
Latest:
Diversity in Urology: Progress made, but there is more work to be doneKelvin Moses, MD, PhD, interviews Tracy M. Downs, MD, about progress and remaining challenges regarding diversity, equity, and inclusion in the field of urology.
Latest:
What steps can physicians take to overcome barriers to health equity?“Things we have control over are ourselves, our care team, and to some extent, our care model,” said Sarah Candler, MD.
Latest:
Recurrence delayed but no OS boost with adjuvant pembrolizumab in urothelial carcinomaAdjuvant pembrolizumab reduced the risk of disease recurrence or death, but did not improve overall survival, compared with observation in patients with urothelial carcinoma.
Latest:
Current Shortcomings in the Modern Urology Practice Management LandscapeA urologist practicing in California defines the remaining general and region-specific challenges he faces in managing his practice and his hopes for future solutions.
Latest:
Closing Thoughts on the Impact of PSMA-PET Imaging in Prostate CancerExperts summarize how the use of PSMA-PET imaging has impacted the field to date and share their hopes for the future.
Latest:
Continued Advances and Unmet Needs in PSMA-Based Imaging for Prostate CancerExperts Naveen Kella, MD, and Dr. Shadi Esfahani, MD, MPH, consider the continued impact of PSMA PET imaging on prostate cancer management and emerging modalities that could revolutionize patient care.
Latest:
Balancing the benefits and risks of AI in health care“The potential benefits of incorporating AI into health care are numerous but like every technology, AI comes with risks that must be managed if the benefits of these tools are to outweigh the potential costs,” writes cybersecurity expert Jon Moore.
Latest:
Expert shares tips for safeguarding your practice when using telehealthHealth care practitioners utilizing telemedicine, regardless of the modality, must be cognizant of the many pitfalls of violating the rules regulating patient confidentiality as established by federal and state privacy laws.
